FLT3 N841Y
Gene Variant Detail

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Gene FLT3
Variant N841Y
Impact List missense
Protein Effect unknown
Gene Variant Descriptions FLT3 N841Y lies within the activation loop of the protein kinase domain of the Flt3 protein (PMID: 25837374). N841Y has been identified in the scientific literature (PMID: 32040554, PMID: 15178581), but has not been biochemically characterized and therefore, its effect on Flt3 protein function is unknown (PubMed, Oct 2025).
Associated Drug Resistance
Category Variants Paths

FLT3 mutant FLT3 exon20 FLT3 N841Y

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Transcript NM_004119.3
gDNA chr13:g.28018487T>A
cDNA c.2521A>T
Protein p.N841Y
Source Database RefSeq
Genome Build GRCh38/hg38
Transcript gDNA cDNA Protein Source Database Genome Build
NM_004119.2 chr13:g.28018487T>A c.2521A>T p.N841Y RefSeq GRCh38/hg38
NM_004119.3 chr13:g.28018487T>A c.2521A>T p.N841Y RefSeq GRCh38/hg38
NM_004119 chr13:g.28018487T>A c.2521A>T p.N841Y RefSeq GRCh38/hg38

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
FLT3 N841Y hematologic cancer sensitive Gilteritinib Preclinical - Cell culture Actionable In a preclinical study, Xospata (gilteritinib) resulted in reduced cell viability in transformed cells expressing FLT3 N841Y in culture (PMID: 32040554). 32040554
FLT3 N841Y hematologic cancer sensitive Gilteritinib Preclinical - Cell culture Actionable In a preclinical study, Xospata (gilteritinib) treatment decreased viability in a cell line expressing FLT3 N841Y in culture (PMID: 40196870). 40196870
FLT3 N841Y acute myeloid leukemia predicted - sensitive Gilteritinib Case Reports/Case Series Actionable In a Phase I trial, Xospata (gilteritinib) resulted in a partial response in an acute myeloid leukemia patient harboring FLT3 N841Y (PMID: 32040554). 32040554
FLT3 N841Y hematologic cancer sensitive Quizartinib Preclinical - Cell culture Actionable In a preclinical study, Vanflyta (quizartinib) treatment decreased viability in a cell line expressing FLT3 N841Y in culture (PMID: 40196870). 40196870
FLT3 N841Y hematologic cancer sensitive Midostaurin Preclinical - Cell culture Actionable In a preclinical study, Rydapt (midostaurin) treatment decreased viability in a cell line expressing FLT3 N841Y in culture (PMID: 40196870). 40196870